⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LBRX News
LB Pharmaceuticals Inc Common Stock
LayerBio Announces FDA Acceptance of Investigational New Drug (IND) Application for OcuRing-K, a Sustained-Release Ketorolac Implant for Cataract Surgery Patients
accessnewswire.com
LBRX
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
globenewswire.com
LBRX
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
LBRX
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
globenewswire.com
LBRX
Form 8-K
sec.gov
LBRX
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
LBRX
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
globenewswire.com
LBRX
Form 8-K
sec.gov
LBRX
Form 8-K
sec.gov
LBRX
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
globenewswire.com
LBRX
NMRA
AMGN
ABT